Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Unknown 3Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 16Lymphoid 14Gastrointestinal 7Thoracic 3Plasma cell 3Other solid neoplasm 3Head & Neck 2Genitourinary 2CNS 2Breast 2Sarcoma 1Myeloid 1Gynecologic 1Dermatologic 1

Conditions

Lung Neoplasms 2Stomach Neoplasms 1Sarcoma, Synovial 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma 1Leukemia, Myeloid 1Glioma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Immunotherapy, Adoptive × Thoracic × Clear all
NCT05268172 2024-05-16

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Affiliated Hospital of Jiangnan University

Phase 1 Unknown
40 enrolled
Thoracic

Pleural Effusion, Malignant

NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

NCT03525782 2018-05-16

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

The First Affiliated Hospital of Guangdong Pharmaceutical University

Phase 1/2 Unknown
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡